Literature DB >> 23159136

Antipyretic therapy in febrile critically ill adults: A systematic review and meta-analysis.

Daniel J Niven1, H Tom Stelfox, Kevin B Laupland.   

Abstract

PURPOSE: To determine whether fever control with antipyretic therapy effects the mortality of febrile critically ill adults.
METHODS: Systematic review using MEDLINE, EMBASE, Cochrane Central Register for Controlled Trials, CINAHL, Google Scholar, and 2 clinical trial registries from inception to April 2012. Randomized clinical trials comparing treatment of fever with no treatment or comparing different thresholds for fever control in adults without acute neurological injury admitted to intensive care units (ICUs) were selected for review. The effect of fever control on all-cause ICU-mortality was determined using a random effects meta-analysis.
RESULTS: Five randomized clinical trials in 399 patients were included. The temperature threshold for treatment in the intervention group was commonly 38.3°C to 38.5°C, whereas it was typically 40.0°C for controls. Four studies used physical measures and 3 used pharmacologic measures for temperature control. There was no significant heterogeneity among the included studies (I(2) = 12.5%, P = .3). Fever control did not significantly effect ICU mortality with a pooled risk ratio of 0.98 (95% confidence interval 0.58-1.63, P = .9).
CONCLUSIONS: This meta-analysis found no evidence that fever treatment influences mortality in critically ill adults without acute neurological injury. However, studies were underpowered to detect clinically important differences.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23159136     DOI: 10.1016/j.jcrc.2012.09.009

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  21 in total

1.  Manipulating vital signs in septic shock: which one(s) and how?

Authors:  Kevin B Laupland; Mathieu van der Jagt
Journal:  Intensive Care Med       Date:  2015-09-10       Impact factor: 17.440

2.  Counterpoint: Should antipyretic therapy be given routinely to febrile patients in septic shock? No.

Authors:  Anne M Drewry; Richard S Hotchkiss
Journal:  Chest       Date:  2013-10       Impact factor: 9.410

Review 3.  Controversies in the temperature management of critically ill patients.

Authors:  Yasufumi Nakajima
Journal:  J Anesth       Date:  2016-06-28       Impact factor: 2.078

Review 4.  Critical care medicine 2013: a review and prospect.

Authors:  Wei Huang
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

5.  Management of severe infections: A time to keep a cool head or a hot topic for clinical trials?

Authors:  Kevin B Laupland; Louis Valiquette
Journal:  Can J Infect Dis Med Microbiol       Date:  2014       Impact factor: 2.471

6.  Management of hyperthermia and hypothermia in sepsis: A recent survey of current practice across UK intensive care units.

Authors:  A Beverly; E Walter; M Carraretto
Journal:  J Intensive Care Soc       Date:  2016-01-26

7.  Fever therapy in febrile adults: systematic review with meta-analyses and trial sequential analyses.

Authors:  Johan Holgersson; Ameldina Ceric; Naqash Sethi; Niklas Nielsen; Janus Christian Jakobsen
Journal:  BMJ       Date:  2022-07-12

8.  Targeted temperature management in intensive care - Do we let nature take its course?

Authors:  Robert Golding; Daniel Taylor; Hannah Gardner; Jonathan N Wilkinson
Journal:  J Intensive Care Soc       Date:  2015-10-01

9.  Paracetamol therapy and outcome of critically ill patients: a multicenter retrospective observational study.

Authors:  Satoshi Suzuki; Glenn M Eastwood; Michael Bailey; David Gattas; Peter Kruger; Manoj Saxena; John D Santamaria; Rinaldo Bellomo
Journal:  Crit Care       Date:  2015-04-13       Impact factor: 9.097

Review 10.  Fever management in intensive care patients with infections.

Authors:  Paul J Young; Manoj Saxena
Journal:  Crit Care       Date:  2014-03-18       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.